Quizartinib 17.7mg Tablets

Quizartinib 17.7mg Tablets represent a highly specialized targeted therapy for the treatment of Acute Myeloid Leukemia (AML), specifically addressing the FMS-like tyrosine kinase 3 (FLT3) mutation. Pharmacologically, quizartinib is a potent, oral, type II FLT3 inhibitor. Unlike type I inhibitors that bind to the active conformation of the kinase, quizartinib selectively binds to the inactive conformation of the FLT3 receptor tyrosine kinase.

The FLT3-ITD (internal tandem duplication) mutation is one of the most common and aggressive driver mutations in AML, leading to the constitutive activation of the FLT3 pathway. This uncontrolled signaling drives the rapid proliferation and survival of leukemic cells. By binding to the receptor with high affinity, Quizartinib 17.7mg Tablets effectively block the phosphorylation of FLT3 and its downstream signaling targets, such as STAT5, MAPK/ERK, and AKT. This inhibition halts the uncontrolled growth of the cancer cells and induces apoptosis (programmed cell death), offering a targeted approach to a disease that historically has a poor prognosis.

Indications / Uses of Quizartinib 17.7mg Tablets

Quizartinib 17.7mg Tablets are indicated for the treatment of adult patients with newly diagnosed Acute Myeloid Leukemia (AML) that is FLT3-ITD positive. Usage is strictly guided by the presence of this specific mutation as detected by an FDA-approved test. The treatment protocol typically involves:

• Combination with Induction Chemotherapy: Used in combination with standard cytarabine and anthracycline induction chemotherapy.
• Combination with Consolidation Chemotherapy: Continued in combination with cytarabine consolidation chemotherapy for patients who achieve remission.
• Maintenance Monotherapy: Prescribed as a standalone maintenance therapy following consolidation chemotherapy to help prevent disease recurrence and prolong overall survival.
• FLT3-ITD Specificity: It is specifically indicated for the FLT3-ITD mutation and is not indicated for the treatment of relapsed or refractory AML, or for AML with other FLT3 mutations (like FLT3-TKD) outside of the approved context.

Key Features

• Type II Inhibitor Specificity: Its mechanism as a type II inhibitor allows for high selectivity for the FLT3-ITD mutation, potentially reducing off-target effects compared to multi-kinase inhibitors.
• Survival Benefit: Clinical trials (such as QuANTUM-First) have demonstrated that adding quizartinib to standard chemotherapy significantly improves overall survival compared to chemotherapy alone in this specific patient population.
• Oral Administration: The tablet formulation allows for oral dosing once daily, which is convenient for the maintenance phase of treatment.
• Targeted Potency: It is designed to sustain deep inhibition of the FLT3 driver mutation, which is critical for controlling the aggressive nature of FLT3-ITD positive AML.

Storage for Quizartinib 17.7mg Tablets

To ensure the pharmacological stability of Quizartinib 17.7mg Tablets, proper storage is critical. Store the medication at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Brief excursions are permitted between 15°C and 30°C (59°F to 86°F). Keep the tablets in their original bottle or blister pack to protect them from light and moisture. Do not store the medication in humid areas like bathrooms. Ensure the container is tightly closed and kept securely out of the reach and sight of children and pets.

Important Note on Quizartinib 17.7mg Tablets

Safety monitoring is paramount when using Quizartinib 17.7mg Tablets due to a Boxed Warning regarding QT prolongation, Torsades de Pointes, and cardiac arrest. The drug can significantly prolong the QT interval (a measure of the heart’s electrical cycle). Therefore, electrocardiograms (ECGs) and electrolytes (potassium and magnesium) must be monitored prior to initiation, weekly during induction and consolidation, and weekly for at least the first month of maintenance therapy.

Because of these risks, quizartinib is available only through a restricted program known as the Vanflyta REMS. Both prescribers and pharmacies must be certified.

Quizartinib is a substrate of CYP3A4. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase drug exposure and the risk of QT prolongation, while strong CYP3A4 inducers can reduce efficacy. Concomitant use with these agents should be managed carefully, often requiring dose adjustments.

The medication can cause fetal harm and is not recommended for pregnant women. Females of reproductive potential and males with female partners should use effective contraception during treatment and for several months after the last dose. Common side effects include neutropenia (low white blood cell count), which increases infection risk, nausea, and mucositis. Always consult your hematologist regarding any new heart palpitations, dizziness, or fainting.